ECSP088081A - Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente - Google Patents

Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente

Info

Publication number
ECSP088081A
ECSP088081A EC2008008081A ECSP088081A ECSP088081A EC SP088081 A ECSP088081 A EC SP088081A EC 2008008081 A EC2008008081 A EC 2008008081A EC SP088081 A ECSP088081 A EC SP088081A EC SP088081 A ECSP088081 A EC SP088081A
Authority
EC
Ecuador
Prior art keywords
therapeutic antibody
detection
diana
ancient
absence
Prior art date
Application number
EC2008008081A
Other languages
English (en)
Inventor
Helmut Lenz
Werner Scheuer
Martina Thier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP088081A publication Critical patent/ECSP088081A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención está relacionada con el campo de los anticuerpos terapéuticos. La invención especialmente está relacionada con un método para la detección del antígeno diana de un anticuerpo terapéutico en una muestra que consiste en los siguientes pasos: a) proporcionar la muestra a analizar, b) incubar dicha muestra con dicho anticuerpo terapéutico bajo las condiciones apropiadas para unir dicho anticuerpo terapéutico a dicho antígeno diana, de manera que se forma un complejo de antígeno diana-anticuerpo terapéutico y c) detectar el complejo formado en (b).
EC2008008081A 2005-07-06 2008-01-04 Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente ECSP088081A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05014618 2005-07-06
EP06004447 2006-03-06

Publications (1)

Publication Number Publication Date
ECSP088081A true ECSP088081A (es) 2008-02-20

Family

ID=36922121

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008081A ECSP088081A (es) 2005-07-06 2008-01-04 Detección de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapéutico correspondiente

Country Status (19)

Country Link
US (1) US20070009976A1 (es)
EP (2) EP2194380A3 (es)
JP (1) JP2008545145A (es)
KR (1) KR20080016939A (es)
AR (1) AR053948A1 (es)
AU (1) AU2006265275A1 (es)
BR (1) BRPI0612591A2 (es)
CA (1) CA2613187A1 (es)
CR (1) CR9635A (es)
EC (1) ECSP088081A (es)
IL (1) IL188317A0 (es)
MA (1) MA29730B1 (es)
MX (1) MX2008000277A (es)
MY (1) MY157955A (es)
NO (1) NO20076662L (es)
NZ (1) NZ564471A (es)
RU (1) RU2008103608A (es)
TW (1) TWI312864B (es)
WO (1) WO2007003420A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1447696A (zh) * 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
HRP20141111T1 (hr) * 2004-07-22 2015-01-02 Genentech, Inc. Sastav her2-protutijela
WO2006039486A2 (en) 2004-10-01 2006-04-13 The Board Of Trustees Of The Leland Stanford Junior University Imaging arrangements and methods therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR101253576B1 (ko) 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US8358354B2 (en) 2009-01-26 2013-01-22 The Board Of Trustees Of The Leland Stanford Junior University Correction of optical abberations
US8248515B2 (en) 2006-02-07 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Variable imaging arrangements and methods therefor
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
PT4241849T (pt) 2011-10-14 2024-10-30 Hoffmann La Roche Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
KR101327542B1 (ko) * 2012-03-15 2013-11-08 광주과학기술원 양자점 기반의 경쟁 면역분석법 및 다중 유세포 분석법을 이용한 시료 중 오염물질의 검출 방법
AU2012232949B2 (en) * 2012-09-28 2014-07-03 Willowtree Holdings Pty Ltd Temporary bulkhead
AR095863A1 (es) 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
CN106163558A (zh) 2014-04-25 2016-11-23 豪夫迈·罗氏有限公司 用曲妥珠单抗‑mcc‑dm1和帕妥珠单抗治疗早期乳腺癌的方法
SI3302551T1 (sl) 2015-05-30 2024-10-30 F. Hoffmann-La Roche Ag Metode zdravljenja predhodno nezdravljenega her2-pozitivnega metastatskega raka dojk
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
EP3562844A1 (en) 2016-12-28 2019-11-06 Genentech, Inc. Treatment of advanced her2 expressing cancer
MY189536A (en) 2017-01-17 2022-02-16 Hoffmann La Roche Subcutaneous her2 antibody formulations
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
EP4171748A1 (en) 2020-06-29 2023-05-03 Genentech, Inc. Pertuzumab plus trastuzumab fixed dose combination

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
EP0931147A1 (en) 1996-10-18 1999-07-28 Genentech, Inc. ANTI-ErbB2 ANTIBODIES
ATE443259T1 (de) * 2001-09-20 2009-10-15 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
HUP0600340A3 (en) * 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies

Also Published As

Publication number Publication date
RU2008103608A (ru) 2009-08-20
IL188317A0 (en) 2008-04-13
TWI312864B (en) 2009-08-01
CA2613187A1 (en) 2007-01-11
EP2194380A3 (en) 2010-07-14
AR053948A1 (es) 2007-05-23
EP1902315A1 (en) 2008-03-26
AU2006265275A1 (en) 2007-01-11
WO2007003420A1 (en) 2007-01-11
JP2008545145A (ja) 2008-12-11
MX2008000277A (es) 2008-03-24
MY157955A (en) 2016-08-30
NO20076662L (no) 2008-04-03
MA29730B1 (fr) 2008-09-01
BRPI0612591A2 (pt) 2010-11-23
EP2194380A2 (en) 2010-06-09
CR9635A (es) 2008-02-20
KR20080016939A (ko) 2008-02-22
NZ564471A (en) 2010-04-30
US20070009976A1 (en) 2007-01-11
TW200741203A (en) 2007-11-01

Similar Documents

Publication Publication Date Title
CR9635A (es) Deteccion de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapeutico correspondiente
ES2528321T3 (es) Detección de a-fucosilación en anticuerpos
EP4273551A3 (en) Multiplexed total antibody and antibody-conjugated drug quantification assay
EP4249605A3 (en) Methods for analyte detection
MX2015012823A (es) Ensayo de combinacion de antigeno-anticuerpo del virus de la hepatitis c (vhc) y metodos y composiciones para usarlo.
WO2013068374A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
NZ609824A (en) Immunochromatography devices, methods and kits
MX358772B (es) Metodo para detectar cancer.
MX369610B (es) Metodos, dispositivos y sistemas para analisis de muestras.
MX2019002918A (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
BR112018007842A2 (pt) imunoensaio para a detecção de cininogênio clivado de alto peso molecular, método, anticorpo isolado, kit para detectar um cininogênio de alto peso molecular clivado (hmwk)
DE602006011756D1 (de) Komplexformierungs- und -trennungsverfahren
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
BR112018017336A2 (pt) método in vitro para detectar um anticorpo para p53 (anticorpo anti-p53) em uma amostra e polipeptídeo de fusão
PE20220004A1 (es) Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh
MX2009012048A (es) Eliminacion de interferencia en inmunoensayos ocasionada por anticuerpos de anti-carbohidrato.
WO2011008831A3 (en) Mass tags for spectrometric analysis of immunoglobulins
EA201692071A1 (ru) Иммуноанализ и антитела для обнаружения хромогранина а
EA201400571A1 (ru) Специфичные к трансресвератролу антитела и их применение
ES2527703B1 (es) Inmunosensor electroquímico para la determinación cuantitativa de la micotoxina fb1
FR2968767B1 (fr) Procede et coffret pour le diagnostic in vitro du cancer de la prostate
CL2009001907A1 (es) Metodo de deteccion precoz de cancer gastrico que comprende detectar la presencia de marcadores especificos de cancer gastrico en muestras de plasma.
CO2019002599A2 (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto
WO2018226098A3 (en) METHODS OF TYPING NEUROLOGICAL DISORDERS AND CANCER, AND DEVICES THEREOF
RU2012127077A (ru) Методика проведения иммунохроматографического анализа для серодиагностики